104 results about "Potential biomarkers" patented technology

The invention discloses a multi-omics causal structure relation learning method based on comparative learning, which comprises the following steps: firstly, respectively constructing corresponding encoders for preprocessed gene mutation and gene expression data, and respectively carrying out feature extraction on two kinds of omics data; then, constructing a projection head with shared parameters to realize cross-modal feature alignment; then, using the aligned features as nodes, and constructing causal graph data through a learnable causal graph structure; constructing a graph neural network to learn causal graph representation, and constructing a contrast loss function; and finally, a model prediction result is obtained through a multi-layer perceptron, a survival prediction loss function is constructed, and a total loss function is obtained for multi-omics causal structure model training. Based on gene mutation and gene expression data, a cross-omics causal structure relationship is constructed and learned through comparative learning, more accurate prognosis prediction is provided for diseases such as acute myelogenous leukemia and the like, and potential biomarkers and key regulatory factors are helped to be found.

The invention discloses a differentiated thyroid cancer lung metastasis risk prediction model construction method and system. 4D Label-free quantitative proteomics analysis and PRM and IHC dual verification are carried out on primary focus paraffin embedded tissue samples of lung metastatic DTC patients and non-lung metastatic DTC patients, and it is found that multiple key differential expression proteins DEPs may become potential biomarkers for predicting the DTC lung metastasis risk. In addition, the sample size is enlarged, three single and combined DTC lung metastasis risk prediction models are respectively constructed based on clinical features and key DEPs expression, then internal verification is performed on the efficiency of the three fitted models, and the optimal model is taken to construct Nomogram. According to the method, help is provided for risk stratification of lung metastasis of DTC patients, and an important basis is provided for formulating clinical individualized treatment schemes and follow-up visit strategies for high-risk patients.

The invention discloses a method for screening a Wilson disease serum exosome miRNA biomarker based on a transcriptomics technology, and belongs to the field of bioinformatics analysis of diseases. According to the invention, the effect of miRNA in WD pathogenesis is discussed by identifying serum exosome miRNA, and a potential biomarker is provided for accurate diagnosis and treatment of the disease. According to the invention, 59 DE-miRNAs are identified by analyzing the expression of differential miRNAs of WD and control group patients, and the DE-miRNAs are related to key approaches such as metabolic regulation, cancer progression, signal transduction and the like. Besides, the reliability of the key DE-miRNA, including miR-451a, miR-204-5p and the like, is confirmed through experimental verification, and the potential of the key DE-miRNA as a non-invasive biomarker is indicated. Research results provide important theoretical basis and new insight for accurate diagnosis of WD and development of potential therapeutic targets.

The invention discloses a method for constructing a blood serum endogenous biomarker and a depression diagnosis model of a depression patient, which couples non-targeting and targeting screening technologies, systematically characterizes endogenous small molecule metabolites in blood serum, identifies differential metabolites between the depression patient and a healthy control group, and determines the blood serum endogenous biomarker and the depression diagnosis model of the depression patient. And then determining a biomarker closely related to depression by using a regression model. According to the invention, potential depression biomarkers such as N-methyl-L-alanine, N-acetylneuraminic acid, N-acetylglycine, thymine ribonucleoside, decanoyl carnitine, aspartic acid-phenylalanine and the like are discovered. The diagnosis model obtained by training according to the ratio of N-acetylglycine to thymine ribonucleoside has the highest accuracy (99%), and healthy and disease samples can be effectively distinguished by using a threshold value 2.434. Therefore, the ratio of N-acetylglycine to thymine ribonucleoside is a potential biomarker capable of realizing rapid and accurate diagnosis of depression.

The invention discloses an immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 and application thereof, and belongs to the field of microbial animal cell lines. The immortalized human pelvic kidney cancer related fibroblast line is named as RPCcaf-X1, and the preservation number of the immortalized human pelvic kidney cancer related fibroblast line is CCTCC (China Center For Type Culture Collection) NO: C2025306. The invention also discloses the application of the immortalized human pelvis and kidney cancer related fibroblast line RPCcaf-X1 in the research of the pathogenic mechanism of the pelvis and kidney cancer. The invention further discloses the application of the immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 in tumor microenvironment research. The invention further discloses the application of the immortalized human pelvic kidney cancer related fibroblast line RPCcaf-X1 in drug screening or research and development. The invention further discloses the application of the immortalized human pelvis and kidney cancer related fibroblast line RPCcaf-X1 in screening of potential biomarkers related to pelvis and kidney cancer.

The invention belongs to the technical field of biological detection, and discloses a screening method of respiratory tract infection related biomarkers based on metatranscriptomics. Respiratory tract infection samples with different clinical phenotypes are subjected to metatranscriptome sequencing, data quality control, comparison and transcript quantification, pathogen and host information is reserved, then genes which are stably expressed or remarkably changed in different groups are identified by combining differential expression analysis and co-expression analysis, and potential biomarkers are obtained. And taking an intersection gene of three machine learning algorithms including an LASSO algorithm, a random forest model and an SVM model to obtain the biomarker. The invention provides a biomarker screening method for rapid and accurate identification of respiratory tract infection.

The application belongs to the technical field of biological detection, and discloses a screening method of respiratory tract infection related biomarkers based on macro-transcriptomics. The application performs macro-transcriptome sequencing on respiratory tract infection samples with different clinical phenotypes, performs data quality control, alignment, transcript quantification, retains pathogen and host information, and then identifies genes stably expressed or significantly changed in different groups by combining differential expression analysis and co-expression analysis, obtains potential biomarkers, and obtains the biomarkers by taking the intersection genes of three machine learning algorithms of LASSO algorithm, random forest model and SVM model. The application provides a screening method of biomarkers for rapid and accurate identification of respiratory tract infection.

The application discloses a breast cancer examination tool based on collagen fiber multi-element fusion analysis, which is used for quantitative analysis of breast tissue collagen fiber structure characteristics and examination of breast tissue cancer level. The application can multidimensionally and comprehensively extract structure information of collagen fibers, and through multi-element fusion analysis of multiple structure parameters, the application improves information complementarity of breast tissue morphological characteristic analysis; the application realizes visualization of collagen fiber structure characteristics by using a pixel level resolution quantitative method and combining with a pseudo-color coding technology, and enhances intuitiveness of information; the application classifies and analyzes three potential biomarkers representing different breast cancer levels, provides a high-precision, automatic and rapid breast cancer level examination method, and has greater application potential compared with a traditional breast cancer examination method.

The invention discloses an application of m6A methyltransferase METTL16 in disuse osteoporosis, and the m6A methyltransferase METTL16 is used as a potential biomarker of the disuse osteoporosis, can be used as a new target spot to resist the disuse osteoporosis, and has a good transformation medical prospect.

The invention provides application of an immune response biomarker in prognosis evaluation of mesenchymal stromal cells in treatment of liver cirrhosis patients, and relates to the technical field of biomedicine, the immune response biomarker comprises MX1 positive monocytes or / and LGALS2 positive monocytes, and the MX1 positive monocytes are MX1 positive monocytes or / and LGALS2 positive monocytes. Screening to obtain a potential biomarker LGALS2 positive mononuclear cell and an MX1 positive mononuclear cell for predicting the MSC treatment dose-effect relationship; compared with a healthy control, the proportion of baseline MX1 positive monocytes of a liver cirrhosis patient is remarkably increased (Plt; 0.01), while the proportion of LGALS2 positive monocytes is significantly reduced (Plt; 0.05) of the substrate (1); the change trend of the biomarker under the same MSC dose and the regulation effect on other immune cell subgroups are identified through sequencing analysis, the dose-effect relationship of MSC-mediated immune regulation can be accurately reflected, and patients with low MSC treatment prognosis recurrence risk can be identified.

The invention relates to the technical field of biomedicine, in particular to application of CCN2 serving as a target spot to preparation of a medicine for diagnosing, preventing and / or treating anti-phospholipid syndrome. The invention provides application of CCN2 serving as a biomarker to diagnosis of APS and other related vasculopathy, application of CCN2 serving as a treatment target to preparation of drugs for preventing and / or treating anti-phospholipid syndromes and an establishment method of an APS related vasculopathy model. According to the invention, it is found for the first time that CCN2 targets in APS blood vessels play a crucial role in promoting proliferation and migration of vascular endothelial cells and vascular smooth muscle cells, a new perspective is provided for knowing cell and molecular mechanisms of vasculopathy, and it is determined that CCN2 can be used as a potential biomarker for diagnosing APS vasculopathy and evaluating disease progression of APS vasculopathy. And potential targets for clinical anti-proliferation treatment.

The present invention relates to an application of a reagent for detecting a biomarker in preparing a product for diagnosing oral squamous cell carcinoma, wherein the reagent for detecting a biomarker comprises a reagent for detecting one or more of miR-331-3p, miR-642a-5p and miR-1282, wherein the reagent for detecting hsa-miR-331-3p, hsa-miR-642a-5p and hsa-miR-1282 is a primer, the upstream primer for detecting hsa-miR-331-3p is shown in SEQ ID NO: 2, the upstream primer for detecting hsa-miR-642a-5p is shown in SEQ ID NO: 3, the upstream primer for detecting hsa-miR-1282 is shown in SEQ ID NO: 4, and the downstream universal primer for detecting hsa-miR-331-3p, hsa-miR-642a-5p and hsa-miR-1282 is shown in SEQ ID NO: 5. The present invention finds that hsa-miR-331-3p is significantly highly expressed in oral squamous cell carcinoma and can be used as a potential biomarker for oral squamous cell carcinoma; the present invention finds that after down-regulating the expression of hsa-miR-331-3p, it can significantly inhibit the proliferation and invasion of oral squamous cell carcinoma cells and can be used as a potential target for the treatment of oral squamous cell carcinoma.

The application discloses a three-dimensional DNA walker biosensor based on SERS as well as a preparation method and application thereof, relates to the technical field of biosensors, and is used for detecting target lncRNA. The biosensor comprises an MB\@DNA\@Au\@Ag compound, a 3D DNA walker and an aptamer. The nucleotide sequence of the ssDNA linker is shown in SEQ ID NO:1. The nucleotide sequence of the 3D DNA walker is SEQ ID NO:7 or SEQ ID NO:8 or a corresponding reverse complementary sequence. The biosensor realizes isothermal autonomous walking of the three-dimensional DNA walker and releases MGITC coded Au@Ag SERS nanolabels through TapSAKI triggered strand displacement and Nb.BbvCI enzymatic cleavage, thereby generating a'signal-on' type Raman output. The detection limit of the biosensor for the AKI early diagnosis potential biomarker TapSAKI is as low as 1.16 fM, and reliable quantification can be realized in the range of 4.30-850 fM. Compared with RT-qPCR (LOD is about 0.26 pM), the biosensor is improved by about 2.3 orders of magnitude in the detection limit of molar concentration.

The invention belongs to the technical field of medical biology, and particularly relates to application of porcine cumulus cell miR-31 in improvement of maturation quality of oocytes, and the nucleotide sequence of the porcine cumulus cell miR-31 is shown as SEQ ID NO.1. The invention also relates to a preparation method of the porcine cumulus cell miR-31. The miR-31 can improve the cumulus expansion level, improve the oocyte quality, enhance the mitochondrial function and reduce oxidative stress, target MAPK8 to participate in a JNK channel, inhibit the apoptosis level of the oocyte and remarkably improve the in-vitro oocyte quality. The miR-31 can be used as a potential biomarker for maturation of oocytes. The results provide a theoretical basis for further discussing the effect of miRNA participating in proliferation and differentiation of animal reproduction related cells and the action mechanism of miRNA on follicle development and oocyte maturation.

The invention provides application of a metabolic marker in pulmonary fibrosis diagnosis or prognosis evaluation, and belongs to the technical field of biological medicine. Systematic analysis of metabonomics discovers that lipid metabolism of a patient suffering from pulmonary fibrosis is remarkably changed, downstream products Palmitoyl ethanolamide and 2-amino-1, 3, 4-octadecantool of lipid metabolism can be used as potential biomarkers for diagnosing pulmonary fibrosis, and objective quantitative indexes are provided for diagnosis and prognosis evaluation of pulmonary fibrosis. The invention proves that the Palmitoyl ethanolamide and the 2-amino-1, 3, 4-octadecantool are obviously related to the lung function injury degree and the concentration of the acute-stage blood inflammation marker of the pulmonary fibrosis patient, and the related characteristics prove that the Palmitoyl ethanolamide and the 2-amino-1, 3, 4-octadecantool can be used as the biomarker for evaluating the prognosis of the patient.

The invention discloses an application of a fusion gene RPL17-C18orf32 as a benzo [g, h, i] perylene acute exposure marker, an in-vitro benzo [g, h, i] perylene acute exposure human lung bronchial epithelial cell model is established, abnormal expression of the fusion gene RPL17-C18orf32 is detected, and RPL17-C18orf32 participates in benzo [g, h, i] perylene acute exposure marker expression. The processes of cell proliferation capacity decline, apoptosis rate increase, cycle disorder, cell DNA damage and the like caused by acute exposure of benzo [g, h, i] perylene, so that the fusion gene RPL17-C18orf32 can be used as a biomarker for acute exposure of benzo [g, h, i] perylene. The invention not only provides a potential biomarker for early diagnosis for evaluating the acute exposure of the benzo [g, h, i] perylene, but also provides a new strategy for developing diseases related to the acute exposure of the benzo [g, h, i] perylene for preventing and treating the acute exposure of the benzo [g, h, i] perylene.

The present invention discloses a hair metabolite marker combination for diagnosing Alzheimer's disease and its application. The hair metabolite marker combination includes triacontanes, erucic acid, heneicosane, behenic acid, tetracosane, 3-hydroxybutyric acid, 15-methylhexadecanoic acid, arachidic acid, heptadecanoic acid, melatonin, stearic acid, tetracosanoic acid, heneicosanoic acid, and docosane. The present invention uses metabolomics methods to study, compare, and analyze the hair metabolites of AD patients, MCI patients, and cognitively normal subjects, explores potential biomarkers that may be contained therein, obtains a group of hair metabolite differences among AD patients, and evaluates the sensitivity and specificity of this group of substances for diagnosing AD. The present invention provides a new marker for the accurate diagnosis of AD and can be used in clinical auxiliary diagnosis of AD to improve diagnostic accuracy.

The invention provides a gout target biomarker screening and traditional Chinese medicine prediction method and device based on single cell sequencing in combination with medicinal and edible substances and network pharmacology. The method comprises the following steps: performing data quality control, preprocessing, clustering and grouping on a data set; screening differentially expressed genes through grouping comparison, and taking an intersection of the differentially expressed genes to obtain candidate genes; constructing a protein interaction PP I network, and identifying a potential biomarker treatment target; constructing a network pharmacology model, and performing traditional Chinese medicine or herbal medicine component prediction on the screened chemical small molecules to obtain candidate medicinal materials; according to the standard of homology of medicine and food, a potential traditional Chinese medicine with homology of medicine and food is provided for a gout treatment scheme. By combining with a biomarker screening technology of modern medicine, potential prediction markers are mined, and a theoretical basis and practical guidance are provided for individualized treatment of gout. A plurality of traditional Chinese medicine components with homology of medicine and food are screened through a network pharmacology method and become potential candidate medicines for treating gout.

This invention discloses a set of biomarkers, reagents, kits, and applications for predicting alcoholic liver disease (ALD), belonging to the field of biomarker technology. The key technical points are: This invention uses non-target metabolomics to analyze plasma from ALD patients and healthy controls to identify potential biomarkers and related metabolic pathways in the plasma of ALD patients. Through human fecal metagenomic sequencing, potential biomarkers in the microbiome of ALD patients are identified, providing a scientific basis for the pathogenesis and early screening of ALD. Furthermore, this invention evaluates the therapeutic effect of L-threonine on ALD and explores its molecular mechanism, providing solid preclinical evidence and theoretical basis for L-threonine as a safe and effective natural metabolite-derived drug for the treatment of ALD, opening new directions for the development of innovative ALD therapies.

The invention provides application of a TTR tetramer in prognosis of a heart failure disease. The invention finds that serum TTR tetramer level reduction and NT-proBNP increase are possibly related to adverse clinical outcome events of heart failure patients, such as total cause death and cardiovascular death; after adjusting potential confounding factors, low TTR levels relate to all-cause death and an increase in all-cause rehospitalization risk. Therefore, the serum TTR tetramer and NT-proBNP can be used as potential biomarkers for prognosis of the heart failure disease and independent predictive factors for occurrence of adverse events. A good prediction index is provided for evaluating and improving prognosis of the heart failure disease, so that the survival rate of a patient is increased, the patient is fully benefited, and the application has huge potential and value in clinical application.

The invention belongs to the technical field of biology, and relates to application of a reagent for detecting LOX gene G473A polymorphism in preparation of a kit for predicting epilepsy susceptibility. In a correlation test, the LOX G473A gene polymorphism shows good diagnostic performance (AUC is equal to 0.8143, sensitivity is equal to 74.29%, and specificity is equal to 88.57%) in the aspect of predicting epilepsy susceptibility, and still keeps a good discrimination level (AUC is equal to 0.8158, sensitivity is equal to 84.21%, and specificity is equal to 78.95%) in a verification test, so that the LOX G473A polymorphism can be used as a potential biomarker for clinical diagnosis of epilepsy diseases.

The invention belongs to the field of pancreatic duct adenocarcinoma prediction, and provides a pancreatic duct adenocarcinoma prediction method and system based on oral flora. The pancreatic ductal adenocarcinoma prediction method based on oral flora comprises the following steps: acquiring relative abundance information of each biomarker in a potential biomarker set for diagnosing pancreatic ductal adenocarcinoma of a to-be-detected person; using the relative abundance information of each biomarker in the biomarker set and a pre-trained multivariate statistical model to obtain a probability value of suffering from pancreatic ductal adenocarcinoma; the method comprises the following steps: performing microbiome difference analysis on saliva, duodenal juice and pancreatic tissue samples of a pancreatic ductal adenocarcinoma patient group and a pancreatic benign disease patient group, and taking an intersection of differential bacteria in the samples to obtain a potential biomarker set for diagnosing the pancreatic ductal adenocarcinoma.

The invention belongs to the technical field of biomedicine, and particularly relates to a method for detecting potential biomarkers of myocardial of an HFpEF mouse based on non-targeted metabonomics, which comprises the following steps: constructing an HFpEF mouse model by combining high fat diet with L-NAME, setting a conventional feeding control group, monitoring myocardial glucose metabolism through longitudinal [18F] FDG PET / CT, collecting myocardial tissues, and performing non-targeted metabonomics detection. And screening differential metabolites through Foldchange greater than or equal to 1.2 or less than or equal to 0.83 and p less than 0.05, and carrying out correlation analysis on the differential metabolites and [18F] FDG SUVmean to obtain 25 potential biomarkers. According to the method, the steps are clear and repeatable, the marker is directly related to myocardial energy metabolism, the diagnosis specificity is improved, and a support is provided for HFpEF targeted therapy research and development and molecular mechanism research.

The invention provides an application of plasma proteomic biomarkers in prognosis evaluation related to long-term life quality of severe novel coronavirus infected patients, and relates to the technical field of biomedicines.The biomarkers comprise CAT, ARCN1, KRT5 and CTSC, and the prognosis evaluation related to the long-term life quality of the severe novel coronavirus infected patients is evaluated through plasma proteomic spectra of the severe novel coronavirus infected patients before MSC treatment. And screening to obtain the potential biomarker for predicting the long-term response of MSC treatment. High-risk crowds with long-term sequelae are identified through the protein biomarker region, the life quality level of a patient after MSC treatment for one year can be accurately predicted, patients more likely to benefit from MSC treatment can be identified, clinical doctors are helped to select applicable crowds before early intervention treatment and MSC infusion, and the clinical experience is improved. And improvement of life quality and long-term prognosis of patients suffering from severe novel coronavirus infection in the rehabilitation period is facilitated.

The application relates to a screening and determining method of an ischemic cerebral stroke animal model biomarker of qi deficiency and blood stasis syndrome, which integrates proteomics and transcriptomics technologies, systematically screens differentially expressed proteins and genes related to the syndrome, and on the basis, constructs various disease animal models, verifies candidate targets by adopting ELISA, simultaneously combines qPCR technology, multi-dimensionally confirms expression changes in the models, further draws ROC curves, calculates AUC values, sensitivity and specificity and other diagnostic performance indexes, evaluates diagnostic potential, and further knocks down and overexpresses differentially expressed genes, deeply excavates potential biomarkers with diagnostic values, and provides scientific bases for objective diagnosis of ischemic cerebral stroke qi deficiency and blood stasis syndrome and exploration of molecular mechanisms.

The invention discloses application of a deubiquitinating enzyme STAMBPL1 as a pancreatic cancer diagnostic kit and in targeted drug development. According to the research, by mining a TCGA-PAAD public data set of a TCGA database, the transcriptome expression level of STAMBPL1 in pancreatic cancer tissue is found to be remarkably higher than that in normal tissue. The research also finds that the proliferation and migration of the human pancreatic cancer cell line PANC-1 can be inhibited in vitro by knocking down the STAMBPL1 through the small interfering RNA, and the mRNA level expression quantity of tumor proliferation and cell cycle related genes is reduced. According to the expression difference of the STAMBPL1 in pancreatic cancer derived from a patient and normal tissue and the experimental results of cell phenotype and gene transcription level expression detection after knockdown, the STAMBPL1 can be possibly used as a potential biomarker of pancreatic cancer and a potential target of a pancreatic cancer diagnostic kit.

The invention discloses an important pathway and marker screening method for acute posterior multifocal squamous epithelium lesion based on a single cell sequencing technology and application of the important pathway and marker screening method for acute posterior multifocal squamous epithelium lesion based on the single cell sequencing technology. An scRNA-seq technology is adopted, and PBMCs from an acute-attack APMPPE patient and a healthy control person are analyzed; according to the present invention, the immunoreaction change of the PBMC cells of the APMPPE patient is identified by using the single cell sequencing technology, and the monocytes are classified in detail according to the difference of the expression modes, such that the panoramic description of the characteristics of the monocytes of the APMPPE patient is achieved, and the potential biomarkers of the monocytes in the peripheral blood of the APMPPE patient are found so as to research the immunopathogenesis of the APMPPE. Research results provide evidence that immune response and melanogenesis dysfunction are related to APMPPE, and in addition, IFITM3 is identified as an immune response key factor for driving APMPPE pathogenesis. And a new perspective is provided for knowing the proinflammatory property and the key effect of the CD16 mononuclear cell in the APMPPE immune pathogenesis.

This invention discloses the application of a substance for detecting piRNA biomarkers, including one or more of the following applications: A1) application in the preparation of products for diagnosing myocardial aging; A2) application in the preparation of products for screening myocardial aging; A3) application in the preparation of products for treating myocardial aging; A4) application in the preparation of products for assessing the condition of myocardial aging; A5) application in the preparation of products for differentiating myocardial aging from other diseases; the piRNA biomarker is piR-hsa-014388, and its nucleotide sequence is shown in SEQ ID No. 1. The piR-hsa-014388 biomarker provided by this invention shows a significantly higher expression level in the plasma of patients with myocardial aging than in healthy controls, indicating that piR-hsa-014388 is a potential biomarker for myocardial aging. The ROC curve of piR-hsa-014388's efficacy in diagnosing patients with myocardial aging shows that piR-hsa-014388 has good diagnostic efficacy.

The invention relates to the technical field of disease diagnosis, in particular to an inflammatory bowel disease pathological slice diagnosis method based on a link algorithm, which comprises the following steps: S1, acquiring an inflammatory bowel disease pathological slice; s2, creating a link algorithm; s3, training the link algorithm in the S2 by using the pathological slice of the inflammatory bowel disease obtained in the S1 to obtain an optimal link algorithm; and S4, inputting pathological slices of the inflammatory bowel disease into the optimal link algorithm in the S3, so as to output diagnosis results of the pathological slices of the inflammatory bowel disease, and enabling the diagnosis results of the plurality of pathological slices of the inflammatory bowel disease to form a report to be exported. According to the method, the link algorithm is established, and the microscopic features of a large number of samples are counted, so that a doctor is assisted in finding potential biomarkers and pathological typing rules of the inflammatory bowel disease, objective quantitative indexes can be provided, subjective deviation of manual interpretation can be reduced, and the consistency of ulcerative colitis diagnosis results can be improved.

The application discloses a state-related convolution sparse model-based electroencephalogram signal pattern recognition method, aiming at the problem that existing convolution sparse coding is difficult to recognize state-related biomarkers, state-shared and state-specific waveforms are used for modeling, and the waveform characteristics of electroencephalogram signals in different states are clearly distinguished. Based on this, the application adopts waveform inconsistency constraints to efficiently identify potential biomarkers related to certain states, and the identified potential biomarkers have good interpretability and can be used as an effective tool for auxiliary medical diagnosis.